Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | RARG | P13631 | 3/20 | 0.44 |
| ▸ | RARA | P10276 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16427337 | 0.86 | MAP3K14 (0.47) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL18211725 | 0.81 | MAP3K14 (0.50) | RARBRARGRARAHTR2AHTR2C | |
| SCHEMBL20858672 | 0.80 | PTGS1 (0.48) | NOTUMPTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL720137 | 0.80 | NOTUM (0.50) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL15898836 | 0.79 | PTGS1 (0.36) | NOTUMPTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL16178963 | 0.78 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL8982307 | 0.78 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL3421790 | 0.78 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL2631356 | 0.78 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL2618847 | 0.78 | BACE1 (0.50) | NOTUMRARBRARGRARAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
| EP-1246820-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049683-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
| CN-1265107-A | indole and 2, 3-indoline derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2000-08-30 | — | — | CN | disclosed |
| EP-1007523-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999005140-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 1999-02-04 | — | — | WO | disclosed |
| US-4333759-A | Herbicidal 5-cyano-2,3-dihydro-benzofuran-2-ones | FISONS LIMITED (GB) | 1982-06-08 | — | — | US | disclosed |
| US-4263037-A | 5-Cyano-2,3-dihydrobenzofurans useful as herbicides | FISONS LIMITED (GB) | 1981-04-21 | — | — | US | disclosed |
| EP-0007719-A2 | Cyanbenzofuran derivatives, processes for their preparation and their use in herbicidal compositions; cyanobenzene, benzodioxepine, benzodioxaphosphepine and benzodioxathiepine derivatives | FBC LIMITED (GB) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | NOTUM 3246/4885RARB 2999/4885RARG 3714/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | NOTUM 3917/4885RARB 372/4885RARG 238/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | NOTUM 3917/4885RARB 372/4885RARG 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.